 |
296 Diseases |  |
92 Trials |
|
92 Trials |  |
3449 News |  |
| «12345678910111213...4849» |
- | pioglitazone / Generic mfg.
Preclinical, Journal: Afriplex GRTTM extract attenuates hepatic steatosis in an in vitro model of NAFLD. (Pubmed Central) - Apr 21, 2024
expression, suggesting that additional experiments are required for its development as a suitable therapeutic option against NAFLD. Importantly, further research is needed to explore its antioxidant role in this model.
- | pioglitazone / Generic mfg.
Journal: Effects of antidiabetic drugs on bone metabolism. (Pubmed Central) - Apr 18, 2024
Importantly, further research is needed to explore its antioxidant role in this model. A descriptive, retrospective study involving 106 patients receiving six groups of antidiabetic drugs: insulin; dipeptidylpeptidase four inhibitors (DPP4i); glucagon-like peptide type 1 receptor agonists (GLP1ra); sulfonylureas; sodium-glucose cotransporter two inhibitors (SGLT2i); and pioglitazone, in which osteocalcin (OC), bone alkaline phosphatase (BAP) and C-terminal telopeptide of collagen type 1 or beta-crosslaps (?-CTx) were determined...This finding highlights the
- | pioglitazone / Generic mfg.
Journal: A Pioglitazone Nanoformulation Designed for Cancer-Associated Fibroblast Reprogramming and Cancer Treatment. (Pubmed Central) - Apr 18, 2024
Treatment with DMON-P results in the downregulation of CAF biomarkers and inhibits tumor growth through the effective delivery of Dox. This innovative approach holds promise as an alternative strategy for enhancing therapeutic outcomes in CAF-abundant tumors, particularly in breast cancer.
- | pioglitazone / Generic mfg.
Preclinical, Journal: Effects of Crocus sativus and its constituent, safranal, and pioglitazone, on systemic inflammation and oxidative stress induced by paraquat aerosol in rats. (Pubmed Central) - Apr 17, 2024
sativus and safranal improved inhaled PQ-induced systemic inflammation and oxidative stress similar to those of dexamethasone and showed synergic effects with pioglitazone suggesting the possible PPAR? receptor-mediated effects of the plant and its constituent.
- || efruxifermin (AKR-001) / Akero Therap
Biomarker, Retrospective data, Review, Journal, MRI: Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis. (Pubmed Central) - Apr 17, 2024
receptor-mediated effects of the plant and its constituent. Several drug classes may reduce LFC in patients with NAFLD without a significant effect on fibrosis; nevertheless, trial duration was small, and confidence in the effect estimates was low.
- ketamine / Generic mfg., sirolimus / Generic mfg., pioglitazone / Generic mfg.
Nearest Neighbor Matching in N-Dimensional Space: A Heuristic Strategy for Treatment Selection in Depression (Griffin Hall) - Apr 14, 2024 - Abstract #SOBP2024SOBP_741;
Market demand from relatedness networks potentially could bypass current top-down regulatory structures plagued by expense, delay, inadequate efficacy and public choice rent-seeking. Current Right-to-Try statutes in many states allow immediate implementation.
- | pioglitazone / Generic mfg.
Journal, IO biomarker: Pioglitazone ameliorates ischemia/reperfusion-induced acute kidney injury via oxidative stress attenuation and NLRP3 inflammasome. (Pubmed Central) - Apr 12, 2024
Pioglitazone improved IRI-induced AKI by attenuating oxidative stress and NLRP3 inflammasome activation. Therefore, pioglitazone has the potential to serve as a novel agent for renal IRI treatment and prevention.
- | cisplatin / Generic mfg., pioglitazone / Generic mfg.
Journal, PARP Biomarker, IO biomarker: Pioglitazone enhances cisplatin's impact on triple-negative breast cancer: Role of PPAR? in cell apoptosis. (Pubmed Central) - Apr 11, 2024
On the other hand, cleaved- poly-ADP ribose polymerase (PARP) and -caspase-9, which are known as pro-apoptotic markers, were upregulated in the combination group compared with the solo treatments. Taken together, the addition of pioglitazone to cisplatin further reduced the viability of MDA-MB-231 cells and enhanced apoptosis compared with chemotherapy alone.
- | pioglitazone / Generic mfg.
Journal: Loss of GCN5L1 exacerbates damage in alcoholic liver disease through ferroptosis activation. (Pubmed Central) - Apr 10, 2024
Pharmaceutical modulation of CISD1 activity is critical for cellular iron homeostasis and ethanol-induced ferroptosis. The GCN5L1/CISD1 axis is crucial for oxidative stress and ethanol-induced ferroptosis in ALD and is a promising avenue for novel therapeutic strategies.
- | pioglitazone / Generic mfg.
Preclinical, Journal: Novel thiazolidin-4-one benzenesulfonamide hybrids as PPAR? agonists: Design, synthesis and in vivo anti-diabetic evaluation. (Pubmed Central) - Apr 8, 2024
Molecular docking studies, molecular dynamic simulations, and protein ligand interaction analysis were also performed for the newly synthesized compounds to investigate their predicted binding pattern and energies in PPAR? binding site.
- | pioglitazone / Generic mfg.
Journal: PPAR gamma agonistic activity of dillapiole: protective effects against diabetic nephropathy. (Pubmed Central) - Apr 2, 2024
binding site. Molecular docking revealed that dillapiole binds to the active site of PPAR?, similar to pioglitazone binding...In HFD?+?STZ induced diabetic mice, dillapiole treatment for 7?days was able to improve renal functions and decrease plasma glucose level to 138.39?
- | Idhifa (enasidenib) / BMS, Servier
Journal: Assessment of CYP-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. (Pubmed Central) - Apr 2, 2024
The parameters for omeprazole increased by 1.86 (90% CI: 1.33, 2.60) and 1.47 (0.93, 2.31)-fold, respectively, compared to omeprazole alone, while those for pioglitazone decreased to 0.80 (90% CI: 0.62, 1.03) and 0.87 (90% CI: 0.65, 1.16)-fold, respectively, in comparison to pioglitazone alone. These findings provide valuable insights into dose recommendations concerning drugs acting as substrates of CYP2D6, CYP2C9, CYP3A4, CYP2C19, and CYP2C8 when administered concurrently with enasidenib.
- pioglitazone / Generic mfg.
Liver stiffness improvement with pioglitazone in brazilian patients with metabolic dysfunction-associated steatohepatitis: a multicentric pilot study (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_2118;
These findings provide valuable insights into dose recommendations concerning drugs acting as substrates of CYP2D6, CYP2C9, CYP3A4, CYP2C19, and CYP2C8 when administered concurrently with enasidenib. The administration of pioglitazone led to an improvement in liver stiffness among MASH patients although there was no difference in metabolic conditions, indicating its potential advantages in managing both diabetes and MASH.
- pioglitazone / Generic mfg.
CD36-mediated hepatocyte-macrophage coordination drives hepatic fibrosis in MASLD (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1088;
CD36 serves as a facilitator for the transfer of lipids from hepatic cells to LAMs, thereby initiating the activation of hepatic stellate cells and promoting the progression of liver fibrosis. The identification of CD36 as a potential therapeutic target offers promising prospects for the treatment of advanced liver fibrosis associated with MASLD.
- pioglitazone / Generic mfg.
Pioglitazone ameliorates fibrotic niche of HBV transgenic mice by restoring NK cell function and inhibiting macrophage activation (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_922;
secretion in NK cells, and inhibits macrophage activation to attenuate hepatic inflammation and fibrosis. Therefore, pioglitazone deserves further study in treating HBV-related liver fibrosis.
- pioglitazone / Generic mfg.
How many real world patients diagnosed with metabolic dysfunction-associated steatohepatitis meet clinical trial eligibility criteria? Findings from a large cohort study of more than 18,000 patients from the United States (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_650;
About 2 out of 10 patients with MASH diagnosed in the real-world setting met standard selecting criteria for enrollment in CTs for MASH without cirrhosis. As recruitment strategies in CTs can vary based on study design and objectives, the real-world evidence from this study brings new insights to inform decisions on inclusion and exclusion criteria.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, Trial completion date: Semaglutide in Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Apr 2, 2024
P4, N=180, Completed, Sponsor: Zagazig University
As recruitment strategies in CTs can vary based on study design and objectives, the real-world evidence from this study brings new insights to inform decisions on inclusion and exclusion criteria. Recruiting --> Completed | Trial completion date: Aug 2024 --> Apr 2024
- || pioglitazone / Generic mfg.
Retrospective data, Review, Journal, Real-world evidence, Real-world: Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database. (Pubmed Central) - Apr 1, 2024
Recruiting --> Completed | Trial completion date: Aug 2024 --> Apr 2024 Both our systematic review/meta-analysis and the real-world dataset show that combination of pioglitazone with either GLP-1RAs or SGLT2 inhibitors is associated with increased weight loss and reduced risk of heart failure compared with monotherapy.
- pioglitazone / Generic mfg.
The omega-3 fatty acid Docosahexaenoic acid overcomes the PKC? deficiency in immature cord blood T cells and regulates maturation towards a Th1 cytokine bias (Exhibit Hall F1; Poster Board Number: B845) - Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_932;
expression. The results show that the ratio of ?-3 (DHA): ?-6 PUFA regulates the transition of the immature Th2 bias at birth to the mature Th1 cytokine propensity, providing avenues for early intervention to reduce the allergy risk.
- | Journal: Different Coactivator Recruitment to Human PPAR?/?/? Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease. (Pubmed Central) - Mar 28, 2024
Only five agonists (bezafibrate, pemafibrate, elafibranor, lanifibranor, and seladelpar) recruited all four coactivators to PPAR?-LBD, and their concentration-dependent responses differed from those of PPAR?/?-LBD. These results indicate that altered gene expression through consensus PPREs by different PPAR subtypes/agonists may be caused, in part, by different coactivators, which may be responsible for the unique pharmacological properties of these PPAR agonists.
- | pioglitazone / Generic mfg.
Journal: Upregulation of PGC-1? expression by pioglitazone mediates prevention of sepsis-induced acute lung injury. (Pubmed Central) - Mar 25, 2024
Mechanistic investigations revealed that PGZ activated the PPAR?/PGC-1?/mitochondrial protection pathway to prevent sepsis-induced ALI by inhibiting M1 macrophage polarization. These results may provide new insights and evidence for developing PGZ as a potential ALI therapy.
- | pioglitazone / Generic mfg.
Trial completion date, Trial primary completion date: PIOGAS: Pioglitazone for Idiopathic Gastroparesis (clinicaltrials.gov) - Mar 21, 2024
P1, N=10, Active, not recruiting, Sponsor: Johns Hopkins University
These results may provide new insights and evidence for developing PGZ as a potential ALI therapy. Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
- | losartan / Generic mfg., pioglitazone / Generic mfg.
Journal: JTT-654, an 11-beta hydroxysteroid dehydrogenase type 1 inhibitor, improves hypertension and diabetic kidney injury by suppressing angiotensinogen production. (Pubmed Central) - Mar 18, 2024
Moreover, JTT-654 did not affect normotension or hypothalamus-pituitary-adrenal (HPA) axis function in normal Sprague-Dawley rats. Our results indicate that JTT-654 ameliorates hypertension and diabetic nephropathy by inhibiting 11?-HSD1 in the adipose tissue, liver, and kidney.
- pioglitazone / Generic mfg.
ASSESSMENT OF JEJUNAL EOSINOPHIL POPULATIONS IN DIABETIC DB/DB MICE FOLLOWING TREATMENT WITH A GREEN ROOIBOS EXTRACT () - Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_1002;
More detailed immunophenotyping may provide better insights into potential immune modulatory effects of GRTTM and pioglitazone. Characterisation of dendritic cells and macrophages and examining the mechanisms leading to the observed increase in pro-inflammatory eosinophil sub-populations in diabetic and aged mice could improve our understanding of inflammatory responses in metabolic diseases and aid in devising new treatment strategies.
- pioglitazone / Generic mfg.
GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS USE IS ASSOCIATED WITH LOWER MORTALITY AND IMPROVEMENT OF CARDIOVASCULAR OUTCOMES IN PATIENTS WITH MAFLD AND OBESITY: A MULTI-CENTER ANALYSIS. (202B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4348;
Only a few pharmacologic treatment options are considered in the current guidelines, such as vitamin E and pioglitazone...Discussion In this multicenter retrospective study, we found that patients with obesity and associated MAFLD who are on GLP-1 RAs have reduced rates of all-cause mortality and major cardiovascular events. Further prospective studies are needed to determine the mechanism for these clinical findings.
- | pioglitazone / Generic mfg.
Journal: Editorial: Integrating transcriptional modulation in systemic tumor therapy. (Pubmed Central) - Mar 14, 2024
Further prospective studies are needed to determine the mechanism for these clinical findings. No abstract available
- | pioglitazone / Generic mfg.
Preclinical, Journal, IO biomarker: Antihyperglycemic effect of extra virgin sacha inchi oil in type 2 diabetic rats: Mechanisms involved in pancreatic ?-cell function and apoptosis. (Pubmed Central) - Mar 14, 2024
No abstract available The rats were then treated for 5 weeks with EVSIO (0.5, 1, and 2
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: TRABEPIO: Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. (clinicaltrials.gov) - Mar 12, 2024
P2, N=10, Recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
The rats were then treated for 5 weeks with EVSIO (0.5, 1, and 2 Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Dec 2024
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal: Comparison between the Effect of empagliflozin and pioglitazone added to metformin in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. (Pubmed Central) - Mar 11, 2024
combination of EMPA or PGZ with metformin equally improved liver fibrosis stage and stiffness in T2DM patients with NAFLD. The improvements of laboratory tests were observed in the both groups, while, regarding weight reduction, only the regimen containing EMPA was effective.
- | pioglitazone / Generic mfg.
Journal: GLP-1 receptor agonists in the treatment of diabetic non-alcoholic steatohepatitis patients. (Pubmed Central) - Mar 9, 2024
These drugs include (in order of relevance), GLP-1 receptor agonists, GLP-1 and GIP dual receptor agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and pioglitazone. The future, FDA-approved drug for diabetic NASH treatment will likely be GLP-1agonist, which could be used as monotherapy or in combination with other drugs.
- Rituxan (rituximab) / Roche
NEPHROLOGY CARE MANAGEMENT IN THE UKRAINIAN WAR: 2 YEARS EXPERIENCE (SUN-120; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1079;
The future, FDA-approved drug for diabetic NASH treatment will likely be GLP-1agonist, which could be used as monotherapy or in combination with other drugs. For CKD 2-4 in cases of non-inherent glomerular diseases with proteinuria raised 0.75 g/l and above in adults and children, rituximab for 1.5 years duration in 3 double doses was used (under the CD 20 control) with daily tacrolimus, iRAAS, and in case of 6 months' fail
- pioglitazone / Generic mfg., rosiglitazone / Generic mfg.
Effectiveness of Apolipoprotein E Targeted Therapeutic Drugs for Alzheimer's Disease: A Systematic Review and Meta-analysis (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_4430;
Drugs targeting Apo-E show little to no efficacy in the treatment of AD. More large-scale trials with Pioglitazone would likely show no beneficial effects, as seen with the Rosiglitazone group.
- | pioglitazone / Generic mfg.
Journal, IO biomarker: Pioglitazone, a peroxisome proliferator?activated receptor ? agonist, induces cell death and inhibits the proliferation of hypoxic HepG2 cells by promoting excessive production of reactive oxygen species. (Pubmed Central) - Mar 7, 2024
agonist stimulated excessive ROS production to inhibit cell proliferation and increase the death of hypoxic HepG2 cells by decreasing BCL2 mRNA expression, suggesting a negative association between PPAR? and BCL2 in the regulation of ROS production in hypoxic HepG2 cells.
- | pioglitazone / Generic mfg.
Preclinical, Journal, IO biomarker: Enhanced upregulation of SIRT1 via pioglitazone and ligustrazine confers protection against ethanol-induced gastric ulcer in rats. (Pubmed Central) - Mar 5, 2024
Our study was the first to show that Piog, Ligu, and (Piog+Ligu) ameliorated oxidative stress, inflammation, and apoptosis and accelerated the autophagic process via the upregulation of the upstream SIRT1 protein. It is worth mentioning that future studies are needed to pave the way for the clinical use of Piog and Ligu as gastro-protective agents.
- | pioglitazone / Generic mfg.
Trial completion date, Trial primary completion date: Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss (clinicaltrials.gov) - Mar 2, 2024
P4, N=54, Recruiting, Sponsor: University of Texas Southwestern Medical Center
It is worth mentioning that future studies are needed to pave the way for the clinical use of Piog and Ligu as gastro-protective agents. Trial completion date: Jan 2024 --> Jul 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
- ||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, P3 data, Journal: A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin. (Pubmed Central) - Mar 1, 2024
Adjunctive pioglitazone treatment in T2DM inadequately controlled with metformin and dapagliflozin demonstrates considerable glycaemic improvement, metabolic benefits, and a low risk of hypoglycaemia. These advantages must be weighed against the potential for weight gain and increased waist circumference.
- || Idhifa (enasidenib) / BMS, Servier
Trial completion: A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients (clinicaltrials.gov) - Feb 28, 2024
P1, N=40, Completed, Sponsor: Celgene
These advantages must be weighed against the potential for weight gain and increased waist circumference. Active, not recruiting --> Completed
- | pioglitazone / Generic mfg., rosiglitazone / Generic mfg.
Journal: Toxicometabolomics-based cardiotoxicity evaluation of Thiazolidinedione exposure in human-derived cardiomyocytes. (Pubmed Central) - Feb 27, 2024
These findings demonstrate the utility of toxicometabolomics in elaborating on mechanisms of drug toxicity and identifying potential biomarkers, thus encouraging its application in the toxicological sciences. (245 words).
- | 5-fluorouracil / Generic mfg.
Preclinical, Journal: PPARG activation promotes the proliferation of colorectal cancer cell lines and enhances the antiproliferative effect of 5-fluorouracil. (Pubmed Central) - Feb 25, 2024
Activation of PPARG increased malignancy associated traits such as proliferation in CRC cell lines but also increases sensitivity towards the chemotherapeutic agent 5-FU. Based on this finding, a combination therapy of PPARG agonists and 5-FU-based chemotherapy constitutes a promising strategy which should be further investigated.
- | metformin / Generic mfg., pioglitazone / Generic mfg.
Journal: Metformin versus metformin plus pioglitazone on gonadal and metabolic profiles in normal-weight women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial. (Pubmed Central) - Feb 24, 2024
In normal-weight women with PCOS, PIOMET treatment may have more benefits in improving SHBG, AMH, and postprandial glucose levels than MET monotherapy, and did not affect weight. However, the study findings need to be confirmed in PCOS study populations with larger sample sizes.
- | pioglitazone / Generic mfg.
Preclinical, Journal: Test of insulin resistance in nondiabetic and streptozotocin-induced diabetic rats using glycosylated hemoglobin test and other interventions. (Pubmed Central) - Feb 23, 2024
Pioglitazone (PGZ) is an oral TZD antidiabetic, whereas chromium-picolinate (Cr-PL) and Cr-glucose tolerance factor (Cr-GTF) are useful type 2 diabetes mellitus (T2DM) supplements...PGZ alone and PGZ + Cr-PL had less pharmacological synergy than Cr-GTF and PGZ in altering insulin and HOMA-IR blood levels. These encouraging discoveries need more study.
- | pioglitazone / Generic mfg.
Journal: Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care. (Pubmed Central) - Feb 22, 2024
This article reviews the role of insulin resistance in the metabolic dysfunction observed in obesity, type 2 diabetes, atherogenic dyslipidemia, and hypertension and how it is a driver of the natural history of NAFLD by promoting glucotoxicity and lipotoxicity. The authors also review the genetic and environmental factors that stimulate steatohepatitis and fibrosis progression and their relationship with cardiovascular disease and summarize guidelines supporting the treatment of NAFLD with diabetes medications that reduce insulin resistance, such as pioglitazone or glucagon-like peptide 1 receptor agonists.
- | pioglitazone / Generic mfg.
Journal: Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies. (Pubmed Central) - Feb 22, 2024
This article reviews current guidance regarding the use of pharmacological agents such as pioglitazone, glucagon-like peptide 1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors in the setting of NAFLD and NASH. It also reviews the latest information on new drugs currently being investigated for the treatment of NASH.
- | pioglitazone / Generic mfg., rosiglitazone / Generic mfg.
Journal: Vimentin protein is a factor for decreasing breast cancer cell proliferation co-culture with human bone marrow-derived mesenchymal stem cells pre-treated with thiazolidinedione solutions. (Pubmed Central) - Feb 21, 2024
It also reviews the latest information on new drugs currently being investigated for the treatment of NASH. The present study identified a novel intracellular protein that may represent the promising target in pre-treated BMSCs to decrease the proliferation of breast cancer MCF-7 cells for human health and wellness.
- | pioglitazone / Generic mfg.
Preclinical, Journal: The antidiabetic drug pioglitazone ameliorates betel-nut-induced carcinogenesis in mice by restoring normal lipid metabolism, reducing oxidative stress, and inducing apoptosis. (Pubmed Central) - Feb 20, 2024
The present study identified a novel intracellular protein that may represent the promising target in pre-treated BMSCs to decrease the proliferation of breast cancer MCF-7 cells for human health and wellness. Pioglitazone can effectively alleviate AEBN-induced carcinogenesis in mice.
- | pioglitazone / Generic mfg.
Preclinical, Journal: Anti-steatotic effects of PPAR-alpha and gamma involve gut-liver axis modulation in high-fat diet-fed mice. (Pubmed Central) - Feb 20, 2024
Treatment with PPAR agonists modulated the gut microbiota and rescued the integrity of the intestinal barrier, alleviating hepatic steatosis. These results show that these agonists can contribute to metabolic-associated fatty liver disease treatment.
- bleomycin / Generic mfg., pioglitazone / Generic mfg.
Mitoneet and Its Regulation of Mitochondrial Metabolism in Pulmonary Hypertension (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_2150;
Pharmacological modulation of mitoNEET activity was accomplished using the thiazolidinedione pioglitazone (Pio), or the compound NL-1. These results suggest that MitoNEET is involved with PASMC proliferation and suggest a new target for therapeutic intervention.
- pioglitazone / Generic mfg.
A "Tail" of Caution: Pioglitazone Induced Recurrent Pleural Effusion (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1587;
This proves our hypothesis that pioglitazone was the causative agent for the pleural effusion. Clinicians should be cognizant of this rare but serious adverse effect and consider alternative medications for the treatment of type 2 diabetes mellitus.
- | pioglitazone / Generic mfg.
Journal: Regulation of the immune microenvironment by pioglitazone-loaded polylactic glycolic acid nanosphere composite scaffolds to promote vascularization and bone regeneration. (Pubmed Central) - Feb 16, 2024
In vivo research using PIO-containing PLGA nanospheres revealed massive collagen deposition in skin models. These findings indicate a potentially effective scaffold for bone healing, when PLGA nanospheres-which contain the drug PIO-are combined with ATP/PVA/GEL scaffolds.
- |||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Trial completion date, Trial primary completion date: Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus (clinicaltrials.gov) - Feb 15, 2024
P3, N=480, Not yet recruiting, Sponsor: EMS
These findings indicate a potentially effective scaffold for bone healing, when PLGA nanospheres-which contain the drug PIO-are combined with ATP/PVA/GEL scaffolds. Trial completion date: Feb 2025 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Mar 2026